552331-73-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-(4-methoxybenzyloxy)pyridine is used as a chemical intermediate for the synthesis of more complex compounds, particularly in the development of new drugs and pharmaceuticals. Its unique structure and functional groups make it a valuable building block in medicinal chemistry.
Used in Chemical Research:
3-Bromo-5-(4-methoxybenzyloxy)pyridine is used as a research compound in the field of organic chemistry. It serves as a starting material for the synthesis of various organic molecules, including those with potential applications in materials science, catalysis, and other areas of chemical research. Its reactivity and stability are often studied to understand its behavior in different chemical reactions and conditions.

InChI:InChI=1/C13H12BrNO2/c1-16-12-4-2-10(3-5-12)9-17-13-6-11(14)7-15-8-13/h2-8H,9H2,1H3

Upstream product

• 625-92-3 3,5-dibromopyridine 
• 53942-86-2 4-methoxybenzyl alcohol sodium salt 
• 74115-13-2 5-bromopyridine-3-ol 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 74115-13-2 5-bromopyridine-3-ol 
• 552331-81-4 5-(4-methoxy-benzyloxy)-2-pyridin-4-yl-[1,7]naphthyridine 
• 552331-77-8 [4-formyl-5-(4-methoxy-benzyloxy)-pyridin-3-yl]-carbamic acid tert-butyl ester 
• 552331-75-6 [5-(4-methoxy-benzyloxy)-pyridin-3-yl]-carbamic acid tert-butyl ester 
• 552331-78-9 5-(4-methoxy-benzyloxy)-1H-[1,7]naphthyridin-2-one 
• 552331-80-3 2-chloro-5-(4-methoxy-benzyloxy)-[1,7]naphthyridine 
• 552331-74-5 3-amino-5-(4-methoxy-benzyloxy)-pyridine 

Relevant academic research and scientific papers

Pharmaceutical compounds

Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Synthesis and structure-activity relationship of 3,4′- bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer

Structure-based design and synthesis of the 3,4′-bispyridinylethylene series led to the discovery of 3-isoquinolinylpyridine 13a as a potent PKB/Akt inhibitor with an IC50 of 1.3 nM against Akt1. Compound 13a shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to marginal selectivity against closely related kinases in the AGC and CMGC families. Moreover, 13a demonstrates potent cellular activity comparable to staurosporine, with IC50 values of 0.42 and 0.59 μM against MiaPaCa-2 and the Akt1 overexpressing FL5.12-Akt1, respectively. Inhibition of phosphorylation of the Akt downstream target GSK3 was also observed in FL5.12-Akt1 cells with an EC50 of 1.5 μM. The X-ray structures of 12 and 13a in complex with PKA in the ATP-binding site were determined.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

A comparison of the binding of three series of nicotinic ligands

A total of 24 aryl-substituted analogues of nicotine (1a) and two related series of nicotinic ligands, aminomethylpyridines 3 and ether analogues 8, were examined to determine if they bind at α4β2 nACh receptors in a common manner. A modest correlation (r=0.785) was found between the affinities of the nicotine analogues and derivatives of 3, but little correlation (r=0.348) was found with analogues 8. However, a modest correlation (r=0.742) exists between the binding of analogues 3 and 8. It seems that 1-series and 8-series compounds bind differently but that the 3-series compounds share some intermediate binding similarity with both.